 |
|
|
| |
Pharmacokinetic (PK) Drug-Drug Interaction between Samatasvir (IDX719), a Pan-Genotypic NS5A Inhibitor, and Simeprevir in Healthy Volunteers and HCV-Infected Subjects
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
X.J. Zhou1, E. Donovan1, J. Chen1, D. Frank1, R. van Heeswijk2, J. Z. Sullivan-Bólyai1, P. Van Remoortere3, R. Verloes2, G. Picchio3, D. Mayers1 and the HELIX-1 Investigator Group
1 Idenix Pharmaceuticals, Inc., Cambridge, MA; 2Janssen Infectious diseases BVBA, Beerse, Belgium; 3 Janssen Research and Development, Titusville, NJ
IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected
Subjects.....http://www.natap.org/2013/HCV/013113_03.htm
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C (April 7, 2014).......http://www.natap.org/2014/HCV/040714_01.htm
HELIX-2, a phase II all-oral combination study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the treatment of hepatitis C has been initiated (12/03/2013).....http://www.natap.org/2013/HCV/120313_02.htm
|
| |
|
|
|
|
|
